<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156473">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999192</url>
  </required_header>
  <id_info>
    <org_study_id>986_TREAT 2b</org_study_id>
    <secondary_id>2013-000114-38</secondary_id>
    <secondary_id>BT986</secondary_id>
    <nct_id>NCT01999192</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis</brief_title>
  <acronym>986</acronym>
  <official_title>A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Serbia: Medicines and Medical Devices Agency</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of three different
      Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active
      rheumatoid arthritis and an inadequate response to MTX alone.

      The overall study duration is 24 weeks followed by a 24 week extension phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned clinical study 986 (TREAT 2b) is a 24-week study in patients with Active
      rheumatoid arthritis (RA) who have had an inadequate response to Methotrexate (MTX) alone.
      The main phase of this study is followed by a 24-week extension phase for subjects meeting
      the respective entry criteria. Patients will be randomized to one of three different Active
      treatment groups or Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects who achieve an ACR20 at week 12 following treatment with Tregalizumab + MTX compared with subjects treated on placebo + MTX</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with an ACR 20 response.</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with an ACR 50 &amp; 70 response.</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with an Disease Activity Score DAS28 &lt;2.6</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with low disease activity DAS28 ≤3.2</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR score</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple Disease Activity Index [SDAI] ≤11</measure>
    <time_frame>week 12 &amp; 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index [CDAI] ≤10</measure>
    <time_frame>week 12 &amp; 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR score individual components</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 score individual components</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of pharmacokinetics</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC, Cmax, Tmax</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of safety, patient reported outcomes &amp; blood tests.</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tregalizumab</intervention_name>
    <arm_group_label>Dose Level 1 Tregalizumab</arm_group_label>
    <arm_group_label>Dose Level 2 Tregalizumab</arm_group_label>
    <arm_group_label>Dose Level 3 Tregalizumab</arm_group_label>
    <other_name>BT061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject demonstrates active RA according to the 1987 American College of Rheumatology
             (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria
             for RA with functional class I-III for ≥6 months.

          2. Subject receives oral or parenteral MTX treatment for ≥12 weeks (overall), with an
             unchanged mode of application and stable MTX dose of ≥15 mg per week (or ≥12.5 mg per
             week in case of MTX intolerance), but no more than the highest locally approved dose
             for RA, for ≥8 weeks prior to baseline. The dose of MTX is expected to remain stable
             throughout the study and may be adjusted only for safety reasons. If applicable, the
             dose of folic acid must be unchanged for ≥8 weeks prior to baseline.

          3. Subject meets the following two criteria at both screening and baseline:  − At least
             6 swollen joints at 28-joint assessment. − At least 6 tender joints at 28-joint
             assessment.

          4. Subject has an erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) above
             the upper limit of normal (ULN) at screening. These tests may be repeated once during
             the screening period at the discretion of the investigator.

          5. Subject is ≥18 and ≤75 years of age.

          6. Subject has a body mass index ≥18 and ≤35 kg/m².

          7. Subject receives treatment with corticosteroids ≤10 mg prednisone equivalent, stable
             for at least 4 weeks prior to baseline and during the study, if applicable.

          8. Subject receives treatment with non-steroidal anti-inflammatory drugs (NSAIDs),
             stable for at least 2 weeks prior to baseline and during the study, if applicable.

          9. Female subjects of childbearing potential: has both a negative serum pregnancy test
             at screening and a negative urine pregnancy test at baseline.

         10. Subject is judged to be in good general health as determined by the investigator
             based upon the results of medical history, laboratory profile, physical examination,
             chest X-ray (within 3 months before screening date is acceptable), and 12−lead
             electrocardiogram (ECG).

         11. Subject has a cluster of differentiation 4 (CD4) cell count of &gt; 400/µl at screening.

        Exclusion Criteria:

          1. Subject has previous exposure to any systemic biologic therapy (e.g., etanercept,
             adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK) or spleen
             tyrosine kinase (SYK) inhibitors, or to Tregalizumab. Previous treatment with an
             anti-TNF agent is allowed only, if all of the following criteria apply: − treatment
             was stopped for reasons other than lack of efficacy or adverse events (AEs) −
             treatment was stopped at least 12 weeks or five half-lives of the compound prior to
             baseline (whichever is longer), and − the treatment period did not exceed 6 weeks.

          2. Subject received treatment with conventional disease-modifying anti-rheumatic drugs
             (DMARDs) apart from MTX in the 12 weeks prior to baseline, and for DMARD leflunomide
             in the 24 weeks prior to baseline (except where specific leflunomide wash-out
             procedures were completed, following applicable guidelines).

          3. Subject has been treated with intra-articular or parenteral administration of
             corticosteroids in the 4 weeks prior to baseline. Inhaled corticosteroids for stable
             medical conditions are allowed.

          4. Subject has undergone joint surgery in the 12 weeks prior to baseline (at joints to
             be assessed within the study) or has undergone major surgery (e.g., abdominal
             surgery) in the 8 weeks prior to baseline.

          5. Subject has a history of acute inflammatory joint disease of an origin other than RA
             or subject has any other rheumatic disease other than RA (e.g., mixed connective
             tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's
             syndrome, fibromyalgia, systemic lupus erythematosus or any arthritis with onset
             prior to age 17 years). However, subjects may have secondary Sjögren's syndrome.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald van Vollenhoven, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Universitetssjukhuset, Solna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Zipp, Diplom Biol.</last_name>
    <phone>+496103801</phone>
    <phone_ext>255</phone_ext>
    <email>daniela_zipp@biotest.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralf Wolter, PhD</last_name>
    <phone>+496103801</phone>
    <phone_ext>217</phone_ext>
    <email>ralf_wolter@biotest.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>St-Jérôme</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Bruntal</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Vilnus</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 11</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kosice - Saca</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>November 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inadequate response to MTX</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>rheumatoid Arthritis</keyword>
  <keyword>Phase 2b</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
